Safety, efficacy, and acceptability of ADV7103 during 24 months of treatment: an open-label study in pediatric and adult patients with distal renal tubular acidosis
Open Access
- 26 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Pediatric Nephrology
- Vol. 36 (7), 1765-1774
- https://doi.org/10.1007/s00467-020-04873-0
Abstract
Background A new prolonged-release formulation of potassium citrate and potassium bicarbonate, ADV7103, has been shown to improve metabolic control, palatability, and gastrointestinal safety in patients with distal renal tubular acidosis (dRTA) when compared to standard of care (SoC) treatments. The present work evaluates safety and efficacy of ADV7103 during 24 months. Methods Thirty pediatric and adult patients were included in an open-label extension study after a phase II/III trial. Safety and tolerability were assessed. Plasma bicarbonate and potassium levels, as well as urine parameters, were evaluated over time. Acceptability, adherence, and quality of life were also assessed. The evolution of clinical consequences of dRTA in the cohort was explored. Results There were 104 adverse events (AEs) reported, but only 9 gastrointestinal events observed in five patients (17%) were considered to be related to ADV7103 treatment. There were no AEs leading to treatment discontinuation. Plasma bicarbonate and potassium levels were in the normal ranges at the different visits, respectively, in 69–86% and 83–93% of patients. Overall adherence rates were ≥ 75% throughout the whole study in 79% patients. An average improvement of quality of life of 89% was reported at 24 months of study. Conclusions Common AEs concerned metabolism and gastrointestinal disorders; the former being related to the disease. Less than half of the gastrointestinal AEs were related to ADV7103 treatment and they were mostly mild in severity. Metabolic parameters were maintained in the normal ranges in most patients. Patient satisfaction was high and adherence to treatment was good and remained stable. Trial registration number Registered as EudraCT 2013-003828-36 on the 3rd of September 2013. Graphical AbstractKeywords
Funding Information
- Advicenne
This publication has 29 references indexed in Scilit:
- Urinary citrate excretion in healthy children depends on age and genderPediatric Nephrology, 2014
- Everything you need to know about distal renal tubular acidosis in autoimmune disease.Rheumatology International, 2014
- Executive Summary of the 2013 International Society for Clinical Densitometry Position Development Conference on Bone DensitometryJournal of Clinical Densitometry, 2013
- Genetic causes and mechanisms of distal renal tubular acidosisNephrology Dialysis Transplantation, 2012
- Development of a WHO growth reference for school-aged children and adolescentsBulletin of the World Health Organization, 2007
- WHO Child Growth Standards based on length/height, weight and ageActa Paediatrica, 2006
- Dosage of potassium citrate in the correction of urinary abnormalities in pediatric distal renal tubular acidosis patientsAmerican Journal of Kidney Diseases, 2002
- Hereditary Distal Renal Tubular Acidosis: New UnderstandingsAnnual Review of Medicine, 2001
- Renal tubular acidosis in childhoodKidney International, 1981
- Renal tubular acidosis in infants and children: Clinical course, response to treatment, and prognosisThe Journal of Pediatrics, 1972